Optimize your pharmaceutical portfolio strategy

Our pipeline data, historical metrics, deals and milestone information and forecasts arm you with the data you need to optimize your company's portfolio.

As a pharmaceutical company, you need to continually evaluate your disease strategy to discern gaps in your portfolio and decide whether to build or buy. Internal candidates need to be assessed against competitors’ pipelines, and assets suitable for expanding your portfolio identified. To do all this, the right data and analysis is essential.

How we can help

Our portfolio strategy solutions give you timely and accurate intelligence you can act on, including:

A wealth of expert insights gathered by our global team of more than 65 journalists and over 300 specialist analysts
The most up-to-date, comprehensive coverage of drugs, companies, epidemiology, diseases, strategy, and pricing and reimbursement trends
Sales forecasts for pipeline candidates and patient-based sales forecasts from surveys of more than 200 physicians per indication
Country-specific treatment algorithms and reimbursement scenarios
Comprehensive and timely market research reports to help you understand macro trends and synthesize key insights so the ‘big picture’ always informs your commercial decisions
Our Ask-the-Analyst™ service that puts you in direct contact with our global analyst team

Datamonitor Healthcare

Profitability Assessment of Branded Generic Inhalers

By Ljlal Syed, Mark Lansdell and David Abramson 28 Jul 2022

This report examines the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic

Datamonitor Healthcare

Immuno-Oncology Overview

By Colin White, Robert Jeng & Jolene Lau 28 Jul 2022

This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well

Datamonitor Healthcare

Webinar: Manufacturing Challenges Facing Cell and Gene Therapy

By Amanda Micklus 20 Jun 2022

As more regenerative medicine products approach clinical testing and commercialization, seize this opportunity to hear detailed insights and industry best practices from preeminent sector experts. You’ll gain a deep understanding of numerous nurdles unique to bringing durable, curative therapies to patients in need.

Datamonitor Healthcare

Global Market Access Webinar

By Louisa Joseph 16 Jun 2022

Join subject-matter experts from Datamonitor Healthcare as they use data and their industry experience to examine the challenges and opportunities brought about by recent global trends in market access. Learn how to navigate this complex terrain, as increasingly restrictive pricing and reimbursement policies are having an adverse effect on sales of launched and pipeline products across many global markets.

In Vivo

In Vivo Outlook 2021 Report

16 Jun 2022

The highly anticipated Outlook 2022 report from Informa Pharma Intelligence is coming soon. Reach the thousands of senior decision makers who eagerly await this pharma industry ranking and review for the year ahead, with sponsorship opportunities that align your brand with our trusted information.

Datamonitor Healthcare, Biomedtracker, Pharmapremia

2019 Q3 Outlook Webinar

By Hardik Patel 16 Jun 2022

Informa Pharma Intelligence presents an essential, free session during which industry analysts present their data-driven views about what to expect during the third quarter of 2019.

Datamonitor Healthcare

Japan Pharma Outlook Webinar Recording

By Ian Haydock 15 Jun 2022

Listen to this insightful presentation of the unique challenges and opportunities faced by Japan Pharma, hosted by the expert analysts from Pharma Intelligence.

Pharma 360

Global Oncology Opportunities & Trends 2025: Key Markets, Indications and Product

13 May 2022

Join Informa Pharma Intelligence for the “Global Oncology Opportunities” webinar!

In Vivo

Outlook 2022: What Next for Pharma After a Year of Innovation and Growth?

02 Mar 2022

Look ahead with our Pharma Outlook 2022 Extract as we discuss what's coming up in the biopharma space.

In Vivo

Five (Non-COVID) Clinical Trial Hits Of 2021

By Alex Shimmings 05 Jan 2022

2021 may have been dominated by the continuing coronavirus pandemic, but that did not stop industry’s more bread and butter R&D activities. Here, In Vivo takes a look at five of the more notable clinical trial hits of the year.

In Vivo

Innovation Trends Point To More Positives For Health Care Investors

By Ashley Yeo 28 Dec 2021

At the end of a turbulent year for health care, COVID-19 is still dominating the thoughts of stakeholders, but CMS patent attorneys Jane Hollywood and Rob Stephen are encouraged by the innovation and investment trends that are making it an exciting time to be in the thick of the action.

In Vivo

How Will Pfizer Leverage External Innovation After BioNTech Jackpot?

By Lucie Ellis-Taitt 22 Nov 2021

Uwe Schoenbeck, CSO of external science and innovation at Pfizer, knows the company set itself a high bar during the COVID-19 pandemic after rapidly bringing a breakthrough vaccine to market. While the circumstances for the development of Comirnaty were truly unique, Pfizer does not expect to rest on its laurels when it comes to innovative R&D.

Pharma Competitive Intelligence

Not all biopharma IPOs are created equal.

18 Nov 2021

Scrip's team of trusted industry experts bring you the mos critical news and analysis on key commercial topics, from licensing to clinical trials, and competitor activity, around the clock. Our global team of journalists and editors use their extensive experience and relationships with regulators, associations, and industry leaders to bring you in-depth insights so you can stay current on the latest market developments. Register for your free trial today to find out what our editors and journalists are reporting on now.

In Vivo

A New Generation Invents Pharma’s Mirrored Future

By Joanne Shorthouse 17 Nov 2021

Young businesses are getting set to disrupt every inch of the healthcare space with digital twin technology. Outlook spoke to two startups on the brink of a data dawn.

In Vivo

Optimism About Alzheimer’s Disease: Gene Therapy, Digital Therapeutics And New Biomarkers

By Ben Comer 14 Oct 2021

Experts in drug development, clinical care and digital therapeutics discuss gaps in the treatment landscape for Alzheimer’s disease, as well as opportunities for prevention and innovation in care delivery.